Bakterije, odporne na antibiotike, se zanašajo na skrivno strategijo preživetja, ki temelji na RNK

St. Jude Children's Research Hospital scientists have discovered a previously unknown mechanism by which antibiotic-tolerant bacteria survive exposure to antibiotics, revealing a hidden RNA-based strategy that allows them to endure treatment and later rebound. The research, published in Cell Host & Microbe, focuses on Streptococcus pneumoniae, a common pathogen responsible for life-threatening infections such as pneumonia, bloodstream infections, and meningitis. The study shows that these bacteria adapt to both antibiotic exposure and immune pressure by altering RNA regulation, enabling them to temporarily withstand treatment and recover once it is stopped. The research team, led by Dr. Jason Rosch of the St. Jude Department of Host-Microbe Interactions, used an infection model to track how S. pneumoniae evolves within a host. They observed that environmental and immune pressures shape the bacteria’s evolutionary trajectory, favoring adaptations that promote survival over resistance. Unlike traditional antibiotic resistance, which involves genetic mutations that permanently alter bacterial function, this new strategy relies on a flexible, population-level approach known as "bet-hedging." In this process, individual bacterial cells adopt different survival states in response to stress, ensuring that a portion of the population survives even when most die. Single-cell analysis revealed that antibiotic-tolerant S. pneumoniae cells reduce their metabolic activity and slow down cellular processes, minimizing the damage caused by antibiotics. This allows them to avoid immediate destruction and later resume growth once treatment ceases. The researchers identified that this adaptive behavior is driven by changes in RNA regulation, specifically mutations in the rny gene, which controls RNA degradation. By modulating RNA quality, tolerant cells prevent the harmful effects of antibiotics and enter a dormant-like state that protects them until conditions improve. Dr. Rosch emphasized that this discovery underscores the complexity of bacterial survival strategies. "Being able to target the bacterial populations that are refractory to antibiotic treatment is absolutely critical," he stated. "We have uncovered a new strategy for how bacteria respond to antibiotics, which provides new insights into how persistent infections develop. These insights could guide strategies to improve antibiotic effectiveness." The study highlights the growing challenge posed by antibiotic-tolerant bacteria, especially among vulnerable patient groups such as children with cancer or immunocompromised individuals. For these patients, bacterial infections can lead to severe complications due to weakened immune systems. Traditional antibiotic treatments often fail against such strains, making it essential to understand alternative survival mechanisms. The findings suggest that future efforts to combat antibiotic-resistant infections should focus not only on eliminating resistant strains but also on disrupting tolerance mechanisms. Researchers believe that targeting RNA regulation pathways, such as those involving the rny gene, could offer new avenues for improving antibiotic efficacy. This approach might involve developing drugs that interfere with bacterial RNA processing, thereby preventing the formation of tolerant subpopulations. The publication of this research marks a significant step forward in understanding how bacteria evade antibiotics. It also raises questions about the broader implications for public health and antimicrobial stewardship. As antibiotic tolerance becomes increasingly prevalent, the need for innovative therapeutic strategies grows ever more urgent. The work conducted by St. Jude researchers offers valuable insights that could shape future studies and interventions aimed at combating persistent infections.